首页> 外文期刊>Molecular imaging >Commentary to 18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi: Imaging Activated Platelets in Clots—Are We Getting There?
【24h】

Commentary to 18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi: Imaging Activated Platelets in Clots—Are We Getting There?

机译:18 F-GP1的评论,F-GP1是一种新型的PET示踪剂,专门用于血栓的高灵敏度,低背景检测:对血凝块中的活化血小板进行成像-我们到那里了吗?

获取原文
       

摘要

Thrombus formation can lead to heart attacks, stroke and pulmonary embolism, which are major causes of mortality. Current standard diagnostic imaging methods detect anatomic abnormalities such as vascular flow impairment but have limitations. By using a targeted molecular imaging approach critical components of a pathology can be selectively visualized and exploited for an improved diagnosis and patient management. The GPIIb/IIIa receptor is abundantly and specifically exposed on activated platelets and is the key receptor in thrombus formation. This commentary describes the current status of GPIIb/IIIa-based PET imaging approaches with a focus on the recently published preclinical data of the small-molecule PET tracer~(18)F-GP1. Areas of future research and potential clinical applications are discussed that may lead to an improved detection of critical thromboembolic events and an optimization of available antithrombotic therapies by tracking activated platelets.
机译:血栓形成可导致心脏病,中风和肺栓塞,这是造成死亡的主要原因。当前的标准诊断成像方法可检测解剖异常,例如血管流量障碍,但有局限性。通过使用靶向分子成像方法,可以选择性地可视化和利用病理学的关键组成部分,以改善诊断和患者管理。 GPIIb / IIIa受体大量特异性地暴露在活化的血小板上,是血栓形成中的关键受体。这篇评论描述了基于GPIIb / IIIa的PET成像方法的当前状态,重点是小分子PET示踪剂〜(18)F-GP1的最新发表的临床前数据。讨论了将来的研究领域和潜在的临床应用领域,这些领域可能通过跟踪活化的血小板来改善对关键血栓栓塞事件的检测,并优化可用的抗血栓形成疗法。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号